Zilico (Gold sponsor)
Zilico was founded in 2006 following a successful research collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN). The company launched ZedScan, its flagship product in 2014 and the product is now in routine use within the NHS. The company is further driving its adoption in both mature healthcare markets and emerging economies.
ZedScan utilizes Electrical Impedance Spectroscopy (EIS) to provide a rapid, reliable and reproducible assessment of the underlying tissue, providing real-time and more accurate diagnostics, overcoming the subjectivity associated with colposcopy. EIS enables objective identification of normal, cancerous and pre-cancerous cells with measurements undertaken at the same time as colposcopy.
With the advent of primary HPV testing in the UK, colposcopy clinics will require a better way of assessing more visually challenging low-grade abnormalities. ZedScan is a non-optical diagnostic method providing real-time, semi quantitative results enabling better patient management.
Zilico has developed its patented Electrical Impedance Spectroscopy into a platform technology for cancer diagnosis and is expanding its product development into other clinical areas such as vulval, oral, anal, and assessing tissue margins during surgery.
DySiS (Bronze sponsor)
The DYSIS Colposcope with DYSISmap is the only adjunctive colposcopy technology recommended by NICE. DYSIS uses a proprietary technology to create an adjunctive map of the cervix, that highlights areas of interest to a clinician and assists with appropriate biopsy site selection.
The unparalleled on-board SMARTtrack documentation system, allows the clinician to monitor cervical changes over time, reassure and educate patients, it provides dynamic teaching tools for trainee’s and transforms colposcopy MDT meetings.
DYSIS Medical Ltd has Headquarters in Edinburgh, and US offices in Tampa, FL. The company is committed to saving lives through the early detection and diagnosis of disease using biophotonic innovations. It aims to be the global leader in automated optical molecular imaging technologies for medical diagnostic and screening applications.